LDN-211904

LDN-211904

CAT N°: 20453
Price:

From 102.00 86.70

LDN-211904 is an inhibitor of erythropoietin-producing hepatocellular carcinoma (Eph) receptors. In particular, it inhibits EphB3 (IC50 = 79 nM), a tyrosine kinase receptor (RTK) subtype expressed during embryonic development and following central nervous system damage and some cancer cell growth.{32145} At 5 µM, this compound was profiled for inhibitory activity against a panel of 288 kinases and found to inhibit most of the EphA and EphB receptor kinase subtypes except for EphA6 and EphA7, and is non-inhibitory towards the non-RTKs screened except for p38?, p38?, and Qik.{32145}

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-(2-chlorophenyl)-6-(4-piperidinyl)-imidazo[1,2-a]pyridine-3-carboxamide, monoethanedioate
  • Correlated keywords
    • 198408-39-7 EphB3 Eph-B3 LDN211904 receptor tyrosine kinase erythropoietin-producing hepatocellular carcinoma RTK
  • Product Overview:
    LDN-211904 is an inhibitor of erythropoietin-producing hepatocellular carcinoma (Eph) receptors. In particular, it inhibits EphB3 (IC50 = 79 nM), a tyrosine kinase receptor (RTK) subtype expressed during embryonic development and following central nervous system damage and some cancer cell growth.{32145} At 5 µM, this compound was profiled for inhibitory activity against a panel of 288 kinases and found to inhibit most of the EphA and EphB receptor kinase subtypes except for EphA6 and EphA7, and is non-inhibitory towards the non-RTKs screened except for p38?, p38?, and Qik.{32145}

We also advise you